Fexinidazole

Structural formula
General
Non-proprietary name	Fexinidazole
other names	1-methyl-2 - {[4- (methylthio) phenoxy] methyl} -5-nitro-1 H -imidazole
Molecular formula	C 12 H 13 N 3 O 3 S
External identifiers / databases
EC number	682-380-3
ECHA InfoCard	100.207.619
PubChem	68792
ChemSpider	62032
DrugBank	DB12265
Wikidata	Q5446115
Drug information
ATC code	P01 CA03
Drug class	Antiprotozoic
properties
Molar mass	279.314 g mol −1
Physical state	firmly
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Caution
H and P phrases	H: 302-312-332
	P: 261-264-280-301 + 312-302 + 352-304 + 340-312-321-330-362 + 364
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Fexinidazole is an active ingredient from the group of nitroimidazoles and is effective against protozoa . Fexidinazole is used for the anti- parasitic treatment of African trypanosomiasis . The drug works by forming reactive amines which have toxic effects on the parasites. Possible side effects in humans include vomiting, nausea, dizziness, headache, weakness, and tremor . Fexinidazole, taken orally for ten days, could represent a breakthrough in the effective therapy and eradication of African trypanosomiasis. The drug was developed by Sanofi and DNDi . In addition, the development of the drug was supported by several EU countries as well as by the Bill & Melinda Gates Foundation .

At the request of Sanofi, the European Medicines Agency has assessed the efficacy and safety of fexinidazole for the treatment of African trypanosomiasis. In its January 2019 report, it published a positive assessment. This will facilitate the national approvals in the affected countries.

Fexinidazole acts in both the first stage and the second stage of African trypanosomiasis. So far, the neurotoxic drugs melarsoprol and nifurtimox have been used in the second stage of the disease.

Individual evidence

↑ ^a ^b Cayman Chemical: Fexinidazole (CAS 59729-37-2) , accessed December 11, 2018.
↑ François Chappuis: Oral fexinidazole for human African trypanosomiasis . In: The Lancet . tape 391 , no. 10116 , January 2018, p. 100-102 , doi : 10.1016 / s0140-6736 (18) 30019-9 .
↑ ^a ^b Sanofi and DNDi apply to the European Medicines Agency to examine a therapy for the treatment of sleeping sickness. Sanofi, January 31, 2018, accessed December 10, 2018 .
↑ Fexinidazole Winthrop HW-2320 , Committee for Medicinal Products for Human Use of the European Medicines Agency. Retrieved September 12, 2019.
↑ Dörries, Rüdiger, Geginat, Gernot: Medical Microbiology: 198 tables; [according to the new AO - with the subjects: Immunology, Virology, Bacteriology, Mycology, Parasitology, Clinical Infectiology, Hygiene] . 3., completely revised. and exp. Ed. Thieme, Stuttgart 2005, ISBN 3-13-125313-4 .

[caymanchem.com-1] Cayman Chemical: Fexinidazole (CAS 59729-37-2) , accessed December 11, 2018.

[2] François Chappuis: Oral fexinidazole for human African trypanosomiasis . In: The Lancet . tape 391 , no. 10116 , January 2018, p. 100-102 , doi : 10.1016 / s0140-6736 (18) 30019-9 .

[Sanofi-3] Sanofi and DNDi apply to the European Medicines Agency to examine a therapy for the treatment of sleeping sickness. Sanofi, January 31, 2018, accessed December 10, 2018 .

[4] Fexinidazole Winthrop HW-2320 , Committee for Medicinal Products for Human Use of the European Medicines Agency. Retrieved September 12, 2019.

[5] Dörries, Rüdiger, Geginat, Gernot: Medical Microbiology: 198 tables; [according to the new AO - with the subjects: Immunology, Virology, Bacteriology, Mycology, Parasitology, Clinical Infectiology, Hygiene] . 3., completely revised. and exp. Ed. Thieme, Stuttgart 2005, ISBN 3-13-125313-4 .